Company / Current Liabilities per Share
4D Molecular Therapeutics, Inc. Current Liabilities per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$0.96
FY2025
5-year range
$0.49 / $0.96
FY2021-FY2025
Trend
+41.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities per Share has increased for 3 consecutive years, from $0.49 in FY2022 to $0.96 in FY2025.
Based on SEC 10-K filings.
0.96 in FY2025 with a 5-year CAGR of -21.6%.
Increased from $0.58 to $0.96 over the past 2 years.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- +25.3%
- 5-Year CAGR
- -21.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 4D Molecular Therapeutics, Inc.'s current liabilities per share has grown for 3 consecutive years.
- In FY2025, current liabilities per share increased 41.9% year-over-year.
- Peak current liabilities per share was recorded in FY2020.
- Lowest current liabilities per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.96 | +41.9% |
| FY2024 | $0.68 | +16.5% |
| FY2023 | $0.58 | +19.0% |
| FY2022 | $0.49 | -20.3% |
| FY2021 | $0.61 | -81.1% |
| FY2020 | $3.23 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026